Taken together, these results indicate that targeting TCTP by using the actionable drug, DHA, is potential combinational strategy enhancing the response to various type of T cell-mediated therapy such as ACT and ICB therapy to treat multiple type of TCTPhigh cancer. The gene discussed is TPT1; the disease is cancer.